Catalent Appoints Lisa Evoli Senior Vice President and Chief Human Resources Officer
01 Agosto 2023 - 10:00AM
Business Wire
Catalent, Inc. (NYSE: CTLT), the leader in enabling the
development and supply of better treatments for patients worldwide,
today announced that Lisa Evoli has been named Senior Vice
President & Chief Human Resources Officer, effective
immediately.
Ms. Evoli joins Catalent from Integra Lifesciences, a global
medical technology company based in Princeton, New Jersey.
“Lisa is a proven leader with more than 25 years of experience
achieving organizational results, building robust talent pipelines,
and creating an inclusive and engaged workforce for a variety of
multinational public companies,” said Alessandro Maselli, President
and Chief Executive Officer of Catalent. “Her deep health industry
knowledge will be highly valuable as we continue to strengthen and
support Catalent’s world-class workforce to create value for all
our stakeholders.”
Prior to her tenure at Integra Lifesciences, Ms. Evoli held
senior leadership roles at TE Connectivity, Johnson & Johnson,
and Motorola. She holds a bachelor’s degree in business
administration from California University of Pennsylvania and a
master’s degree in human resources development from Villanova
University.
She will be responsible for leading Catalent’s global human
resources strategy, including talent acquisition, leadership
development, diversity and inclusion, organizational design,
compensation and benefits, HR operations and technology, and
performance management.
Ms. Evoli replaces Ricardo Pravda, who will assume the role of
Chief Transformation Officer. As part of this new role, Mr. Pravda
will assist with the Human Resources aspects of Catalent’s ongoing
network portfolio review, which will enable the company to unlock
incremental value and require senior executive engagement across
the company.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the
global leader in enabling pharma, biotech, and consumer health
partners to optimize product development, launch, and full
life-cycle supply for patients around the world. With broad and
deep scale and expertise in development sciences, delivery
technologies, and multi-modality manufacturing, Catalent is a
preferred industry partner for personalized medicines, consumer
health brand extensions, and blockbuster drugs. Catalent helps
accelerate over 1,000 partner programs and launch over 150 new
products every year. Its flexible manufacturing platforms at over
50 global sites supply around 80 billion doses of nearly 8,000
products annually. Catalent’s expert workforce of approximately
18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly
$5 billion in revenue in its 2022 fiscal year. For more information
www.catalent.com.
More products. Better treatments. Reliably supplied.™
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230801750492/en/
Media Bernie Clark +1 (732) 537-6400 media@catalent.com
Investors Paul Surdez +1 (732) 537-6325
investors@catalent.com
Catalent (NYSE:CTLT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Catalent (NYSE:CTLT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024